JP2010522540A - キメラ抗原 - Google Patents

キメラ抗原 Download PDF

Info

Publication number
JP2010522540A
JP2010522540A JP2009554098A JP2009554098A JP2010522540A JP 2010522540 A JP2010522540 A JP 2010522540A JP 2009554098 A JP2009554098 A JP 2009554098A JP 2009554098 A JP2009554098 A JP 2009554098A JP 2010522540 A JP2010522540 A JP 2010522540A
Authority
JP
Japan
Prior art keywords
polypeptide
protein
rsv
chimeric
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009554098A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010522540A5 (cg-RX-API-DMAC7.html
Inventor
ノルマン・ブレ
ダヴィッド・エス・ビュル
ソーニャ・エル・シール
デニ・エル・マルタン
パトリック・ルオー
Original Assignee
アイディー バイオメディカル コーポレイション オブ ケベック
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイディー バイオメディカル コーポレイション オブ ケベック filed Critical アイディー バイオメディカル コーポレイション オブ ケベック
Publication of JP2010522540A publication Critical patent/JP2010522540A/ja
Publication of JP2010522540A5 publication Critical patent/JP2010522540A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009554098A 2007-03-21 2008-03-20 キメラ抗原 Pending JP2010522540A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89620107P 2007-03-21 2007-03-21
PCT/IB2008/001286 WO2008114149A2 (en) 2007-03-21 2008-03-20 Chimeric antigens

Publications (2)

Publication Number Publication Date
JP2010522540A true JP2010522540A (ja) 2010-07-08
JP2010522540A5 JP2010522540A5 (cg-RX-API-DMAC7.html) 2011-05-12

Family

ID=39766560

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009554098A Pending JP2010522540A (ja) 2007-03-21 2008-03-20 キメラ抗原

Country Status (5)

Country Link
US (1) US20100203071A1 (cg-RX-API-DMAC7.html)
EP (1) EP2181121A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010522540A (cg-RX-API-DMAC7.html)
CA (1) CA2684578A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008114149A2 (cg-RX-API-DMAC7.html)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013031827A1 (ja) 2011-08-29 2013-03-07 国立大学法人徳島大学 Rsv粘膜ワクチン
KR20140043348A (ko) * 2011-04-26 2014-04-09 몰레큘라 익스프레스 인코포레이티드 리포솜 제제
JP2015514132A (ja) * 2012-04-10 2015-05-18 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒト呼吸器合胞体ウイルスコンセンサス抗原、核酸構築物、およびそれらから作製されるワクチン、ならびにその使用方法
JP2015524660A (ja) * 2012-08-01 2015-08-27 バヴァリアン・ノルディック・アクティーゼルスカブ 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン
JP2015525794A (ja) * 2012-08-06 2015-09-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
JP2018172417A (ja) * 2012-08-06 2018-11-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
JP2019068833A (ja) * 2012-08-01 2019-05-09 バヴァリアン・ノルディック・アクティーゼルスカブ 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン
WO2020175660A1 (ja) 2019-02-28 2020-09-03 Ｋｍバイオロジクス株式会社 Ｒｓｖ ｆ／ｇキメラワクチン

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160000902A1 (en) * 2003-07-11 2016-01-07 Novavax, Inc. Combination vaccine for respiratory syncytial virus and influenza
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
EP4206231A1 (en) 2007-12-24 2023-07-05 ID Biomedical Corporation of Quebec Recombinant rsv antigens
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
US10328133B2 (en) 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
EP3718566B1 (en) * 2008-12-09 2024-06-12 Novavax, Inc. Modified rsv f proteins and methods of their use
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
HRP20160798T1 (hr) 2009-06-24 2016-08-12 Glaxosmithkline Biologicals S.A. Rekombinantni antigeni iz rsv
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
CN102639147B (zh) 2009-07-15 2015-11-25 诺华股份有限公司 Rsv f 蛋白组合物和其制作方法
WO2011007961A2 (en) * 2009-07-17 2011-01-20 Industry Academic Cooperation Foundation, Hallym University Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes
JP5926180B2 (ja) 2009-07-31 2016-05-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 寛容原性療法のための細胞のプログラミングの方法
AU2010279492B2 (en) * 2009-08-04 2015-04-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of The Health And Human Services, Centers For Disease Control And Prevention Anti-RSV immunogens and methods of immunization
CA2799934C (en) 2010-07-07 2020-01-28 Artificial Cell Technologies, Inc. Respiratory syncytial virus antigenic compositions and methods
EP2624873B1 (en) 2010-10-06 2019-12-04 President and Fellows of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
US20140024076A1 (en) * 2011-01-28 2014-01-23 Medimmune, Llc. Expression Of Soluble Viral Fusion Glycoproteins In Mammalian Cells
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
ES2685327T3 (es) 2011-04-28 2018-10-08 President And Fellows Of Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
SG194755A1 (en) 2011-05-13 2013-12-30 Novartis Ag Pre-fusion rsv f antigens
EP2714073B1 (en) 2011-06-03 2021-03-10 President and Fellows of Harvard College In situ antigen-generating cancer vaccine
ES2395677B1 (es) * 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
SG11201400999VA (en) * 2011-09-30 2014-07-30 Novavax Inc Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
LT2838515T (lt) 2012-04-16 2020-03-10 President And Fellows Of Harvard College Mezoporinės silico dioksido kompozicijos, skirtos imuninio atsako moduliavimui
SG11201506197TA (en) * 2013-02-11 2015-09-29 Novavax Inc Combination vaccine for respiratory syncytial virus and influenza
EP3030260A1 (en) 2013-08-05 2016-06-15 GlaxoSmithKline Biologicals S.A. Combination immunogenic compositions
WO2015168379A2 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
JP6664338B2 (ja) 2014-06-13 2020-03-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組合せ物
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
CN107708756A (zh) 2015-04-10 2018-02-16 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
KR102758377B1 (ko) 2015-09-03 2025-01-23 노바백스, 인코포레이티드 개선된 안정성 및 면역원성을 갖는 백신 조성물
KR102136678B1 (ko) 2015-12-23 2020-07-22 화이자 인코포레이티드 Rsv f 단백질 돌연변이체
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
ES3032115T3 (en) 2016-07-13 2025-07-15 Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
WO2018026884A1 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomaterials for modulating immune responses
WO2018026941A1 (en) 2016-08-03 2018-02-08 Lonza Walkersville, Inc. Method of detecting an endotoxin using limulus amebocyte lysate substantially free of coagulogen
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
KR102545029B1 (ko) * 2017-01-11 2023-06-19 론자 워커스빌 아이엔씨. 맑고 밝게된 무-코아굴로겐 리물루스 아메바세포 용해물
JP7317796B2 (ja) 2017-07-24 2023-07-31 ノババックス，インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
CA3079048A1 (en) 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa Adenoviral vectors with two expression cassettes encoding rsv antigenic proteins or fragments thereof
WO2019076892A1 (en) 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa ENHANCED PROMOTER
WO2019076880A1 (en) 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa SIMIENS ADENOVIRAL VECTORS COMPRISING TWO EXPRESSION CASSETTES
WO2019108541A1 (en) * 2017-11-28 2019-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant rsv g proteins and their use
IL305911B2 (en) 2018-03-19 2025-01-01 Novavax Inc Multifunctional nanoparticle influenza vaccines
EP3807298A1 (en) 2018-06-12 2021-04-21 GlaxoSmithKline Biologicals S.A. Adenovirus polynucleotides and polypeptides
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
KR102725189B1 (ko) 2018-11-01 2024-10-31 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
CN114993784B (zh) * 2022-05-27 2025-07-29 重庆医科大学 一种乙肝病毒颗粒裂解液及其制备与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001516583A (ja) * 1997-09-19 2001-10-02 アメリカン・サイアナミド・カンパニー Ｒｓウイルスの付着（ｇ）タンパク質由来のペプチド

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001516583A (ja) * 1997-09-19 2001-10-02 アメリカン・サイアナミド・カンパニー Ｒｓウイルスの付着（ｇ）タンパク質由来のペプチド

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013018163; Ｊ．　Ｖｉｒｏｌ．，　２０００，　Ｖｏｌ．７４，　Ｎｏ．２２，　ｐ．１０２８７-１０２９２ *
JPN6013018164; Ｊ．　Ｖｉｒｏｌ．，　２００５，　Ｖｏｌ．７９，　Ｎｏ．７，　ｐ．４５２７-４５３２ *
JPN6013018166; Ｊ．　Ｇｅｎ．　Ｖｉｒｏｌ．，　２００６，　Ｖｏｌ．８７，　ｐ．１６５９-１６６７ *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140043348A (ko) * 2011-04-26 2014-04-09 몰레큘라 익스프레스 인코포레이티드 리포솜 제제
JP2014518620A (ja) * 2011-04-26 2014-08-07 モレキュラー エクスプレス，インコーポレイテッド リポソーム製剤
KR101998431B1 (ko) 2011-04-26 2019-07-09 몰레큘라 익스프레스 인코포레이티드 리포솜 제제
WO2013031827A1 (ja) 2011-08-29 2013-03-07 国立大学法人徳島大学 Rsv粘膜ワクチン
US10040828B2 (en) 2012-04-10 2018-08-07 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
JP2015514132A (ja) * 2012-04-10 2015-05-18 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒト呼吸器合胞体ウイルスコンセンサス抗原、核酸構築物、およびそれらから作製されるワクチン、ならびにその使用方法
JP2018065824A (ja) * 2012-04-10 2018-04-26 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒト呼吸器合胞体ウイルスコンセンサス抗原、核酸構築物、およびそれらから作製されるワクチン、ならびにその使用方法
JP2021137023A (ja) * 2012-08-01 2021-09-16 バヴァリアン・ノルディック・アクティーゼルスカブ 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン
JP2019068833A (ja) * 2012-08-01 2019-05-09 バヴァリアン・ノルディック・アクティーゼルスカブ 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン
JP2015524660A (ja) * 2012-08-01 2015-08-27 バヴァリアン・ノルディック・アクティーゼルスカブ 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン
JP7317896B2 (ja) 2012-08-01 2023-07-31 バヴァリアン・ノルディック・アクティーゼルスカブ 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン
JP2018172417A (ja) * 2012-08-06 2018-11-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
JP2015525794A (ja) * 2012-08-06 2015-09-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
WO2020175660A1 (ja) 2019-02-28 2020-09-03 Ｋｍバイオロジクス株式会社 Ｒｓｖ ｆ／ｇキメラワクチン
KR20210134670A (ko) 2019-02-28 2021-11-10 케이엠 바이올로직스 가부시키가이샤 Rsv f/g 키메라 백신
US12121578B2 (en) 2019-02-28 2024-10-22 Km Biologics Co., Ltd. RSV F/G chimeric vaccine

Also Published As

Publication number Publication date
EP2181121A4 (en) 2012-07-11
WO2008114149A2 (en) 2008-09-25
EP2181121A2 (en) 2010-05-05
WO2008114149A3 (en) 2011-04-21
US20100203071A1 (en) 2010-08-12
CA2684578A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
JP2010522540A (ja) キメラ抗原
JP5711972B2 (ja) 組換えｒｓｖ抗原
JP5796011B2 (ja) ワクチン
US9492531B2 (en) Recombinant RSV vaccines
JP2011528222A (ja) キメラ呼吸器合胞体ウイルスポリペプチド抗原
US20160122398A1 (en) Recombinant rsv antigens
HK40091519A (en) Recombinant rsv antigens
HK40092189A (en) Recombinant rsv antigens
HK40085221A (en) Recombinant rsv antigens
HK40083885A (en) Recombinant rsv antigens
AU2013201836B2 (en) Recombinant RSV antigens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110322

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130423

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131001